

To: 5.1.2e | 5.1.2e | 5.1.2e | @rivm.nl]; 5.1.2e | 5.1.2e | 5.1.2e | @rivm.nl]
From: 5.1.2e | 5.1.2e
Sent: Sat 2/27/2021 5:45:32 PM
Subject: Doorst: Placeholder - Extraordinary NFP for Microbiology meeting, 11 March at 15:00
Received: Sat 2/27/2021 5:45:33 PM

11 maart: Bijeenkomst over sequence capaciteit in memberstates voor SARS-CoV2 voor NFPM - er is een nieuwe voorzitter (5.1.2e) sinds het vertrek van 5.1.2e.

Graag input- wat kan ik delen?

Ik ben een beetje verbaasd dat dit met de NFPMicrobiology wordt besproken.

Is het ook al elders besproken?

5.1.2e

Van: PHF Support <5.1.2e @ecdc.europa.eu>
Datum: 26 februari 2021 om 18:50:44 CET
Aan: 5.1.2e @ages.at' <5.1.2e @ages.at>, 5.1.2e @sciensano.be'
<5.1.2e @sciensano.be>, 5.1.2e @ncipd.org' <5.1.2e @ncipd.org>, 5.1.2e @miz.hr'
<5.1.2e @miz.hr>, 5.1.2e @mphs.moh.gov.cy' <5.1.2e @mphs.moh.gov.cy>, 5.1.2e @szu.cz'
<5.1.2e @szu.cz>, 5.1.2e @ssi.dk' <5.1.2e @ssi.dk>, 5.1.2e @terviseamet.ee' <5.1.2e @terviseamet.ee>,
<5.1.2e @thl.fi' <5.1.2e @thl.fi>, 5.1.2e @sanepubliquefrance.fr'
<5.1.2e @sanepubliquefrance.fr>, 5.1.2e @rki.de' <5.1.2e @rki.de>, 5.1.2e @nnk.gov.hu'
<5.1.2e @nnk.gov.hu>, 5.1.2e @landspitali.is' <5.1.2e @landspitali.is>, 5.1.2e @beaumont.ie'
<5.1.2e @beaumont.ie>, 5.1.2e @iss.it' <5.1.2e @iss.it>, 5.1.2e @aslimnica.lv'
<5.1.2e @aslimnica.lv>, 5.1.2e @nvspl.lt' <5.1.2e @nvspl.lt>, 5.1.2e @lns.etat.lu'
<5.1.2e @lns.etat.lu>, 5.1.2e @ms.etat.lu' <5.1.2e @ms.etat.lu>, 5.1.2e @gov.mt'
<5.1.2e @gov.mt>, 5.1.2e <5.1.2e @rivm.nl>, 5.1.2e @fhi.no' <5.1.2e @fhi.no>,
<5.1.2e @nil.gov.pl' <5.1.2e @nil.gov.pl>, 5.1.2e @insa.min-saude.pt' <5.1.2e @insa.min-
saude.pt>, 5.1.2e @cantacuzino.ro' <5.1.2e @cantacuzino.ro>, 5.1.2e @vzbb.sk' <5.1.2e @vzbb.sk>,
<5.1.2e @nlzoh.si' <5.1.2e @nlzoh.si>, 5.1.2e @isci.es' <5.1.2e @isci.es>, 5.1.2e
<5.1.2e @folkhalsomyndigheten.se' <5.1.2e @folkhalsomyndigheten.se>
CC: 5.1.2e @ordensklinikum.at' <5.1.2e @ordensklinikum.at>, 5.1.2e @sciensano.be'
<5.1.2e @sciensano.be>, 5.1.2e @gmail.com' <5.1.2e @gmail.com>, 5.1.2e @hzjz.hr'
<5.1.2e @hzjz.hr>, 5.1.2e @mphs.moh.gov.cy' <5.1.2e @mphs.moh.gov.cy>, 5.1.2e
<5.1.2e @szu.cz>, 5.1.2e @ssi.dk' <5.1.2e @ssi.dk>, 5.1.2e @thl.fi'
<5.1.2e @thl.fi>, 5.1.2e @sanepubliquefrance.fr'
<5.1.2e @sanepubliquefrance.fr>, 5.1.2e @rki.de' <5.1.2e @rki.de>, 5.1.2e @eody.gov.gr'
<5.1.2e @eody.gov.gr>, 5.1.2e @nnk.gov.hu' <5.1.2e @nnk.gov.hu>, 5.1.2e @landspitali.is'
<5.1.2e @landspitali.is>, 5.1.2e @iss.it' <5.1.2e @iss.it>, 5.1.2e @spkc.gov.lv'
<5.1.2e @spkc.gov.lv>, 5.1.2e @nvspl.lt' <5.1.2e @nvspl.lt>, 5.1.2e @lns.etat.lu'
<5.1.2e @lns.etat.lu>, 5.1.2e @gov.mt' <5.1.2e @gov.mt>, 5.1.2e @fhi.no'
<5.1.2e @rivm.nl>, 5.1.2e @fhi.no' <5.1.2e @fhi.no>, 5.1.2e @fhi.no'
<5.1.2e @fhi.no>, 5.1.2e @pzh.gov.pl' <5.1.2e @pzh.gov.pl>, 5.1.2e @yahoo.com'
<5.1.2e @yahoo.com>, 5.1.2e @vzbb.sk' <5.1.2e @vzbb.sk>, 5.1.2e @nlzoh.si'
<5.1.2e @nlzoh.si>, 5.1.2e @isci.es' <5.1.2e @isci.es>, 5.1.2e @folkhalsomyndigheten.se'
<5.1.2e @folkhalsomyndigheten.se>, 5.1.2e @sozialministerium.at' <5.1.2e @sozialministerium.at>,
<5.1.2e @bmw.gv.at' <5.1.2e @bmw.gv.at>, 5.1.2e @sciensano.be' <5.1.2e @sciensano.be>,
<5.1.2e @sciensano.be' <5.1.2e @sciensano.be>, 5.1.2e @ncipd.org' <5.1.2e @ncipd.org>,
<5.1.2e @hzjz.hr' <5.1.2e @hzjz.hr>, 5.1.2e @hzjz.hr' <5.1.2e @hzjz.hr>, 5.1.2e @moh.gov.cy'
<5.1.2e @moh.gov.cy>, 5.1.2e @cytanet.com.cy' <5.1.2e @cytanet.com.cy>, 5.1.2e @szu.cz'
<5.1.2e @szu.cz>, 5.1.2e @szu.cz' <5.1.2e @szu.cz>, 5.1.2e @sst.dk' <5.1.2e @sst.dk>,
<5.1.2e @terviseamet.ee' <5.1.2e @terviseamet.ee>, 5.1.2e @terviseamet.ee' <5.1.2e @terviseamet.ee>,
<5.1.2e @thl.fi' <5.1.2e @thl.fi>, 5.1.2e @thl.fi'

5.1.2e @santepubliquefrance.fr>, 5.1.2e @rki.de' < 5.1.2e @rki.de>, 5.1.2e @rki.de' < 5.1.2e @rki.de>,
 5.1.2e @rki.de' < 5.1.2e @rki.de>, 5.1.2e @eody.gov.gr' < 5.1.2e @eody.gov.gr>, 5.1.2e @nnk.gov.hu'
 < 5.1.2e @nnk.gov.hu>, 5.1.2e @nnk.gov.hu' < 5.1.2e @nnk.gov.hu>, 5.1.2e @nnk.gov.hu'
 < 5.1.2e @nnk.gov.hu>, 5.1.2e @landlacknir.is' < 5.1.2e @landlacknir.is>, 5.1.2e @hse.ie'
 < 5.1.2e @hse.ie>, 5.1.2e @hse.ie' < 5.1.2e @hse.ie>, 5.1.2e @sanita.it'
 < 5.1.2e @sanita.it>, 5.1.2e @spkc.gov.lv' < 5.1.2e @spkc.gov.lv>, 5.1.2e @llv.li'
 < 5.1.2e @llv.li>, 5.1.2e @sam.lt' < 5.1.2e @sam.lt>, 5.1.2e @sam.lt'
 < 5.1.2e @sam.lt>, 5.1.2e @ms.etat.lu' < 5.1.2e @ms.etat.lu>, 5.1.2e @gov.mt'
 < 5.1.2e @gov.mt>, 5.1.2e @rivm.nl' < 5.1.2e @rivm.nl>, 5.1.2e @pzh.gov.pl'
 < 5.1.2e @rivm.nl>, 5.1.2e @fhi.no' < 5.1.2e @fhi.no>, 5.1.2e @pzh.gov.pl>, 5.1.2e @dgs.min-saude.pt'
 < 5.1.2e @pzh.gov.pl>, 5.1.2e @pzh.gov.pl' < 5.1.2e @pzh.gov.pl>, 5.1.2e @dgs.min-saude.pt' < 5.1.2e @dgs.min-saude.pt>, 5.1.2e @dgs.min-saude.pt' < 5.1.2e @dgs.min-saude.pt>, 5.1.2e @insp.gov.ro' < 5.1.2e @insp.gov.ro>, 5.1.2e @uvzsr.sk' < 5.1.2e @uvzsr.sk>, 5.1.2e @uvzsr.sk' < 5.1.2e @uvzsr.sk>, 5.1.2e @nijz.si' < 5.1.2e @nijz.si>, 5.1.2e @nijz.si'
 < 5.1.2e @nijz.si>, 5.1.2e @mssi.es' < 5.1.2e @mssi.es>, 5.1.2e @folkhalsomyndigheten.se'
 < 5.1.2e @folkhalsomyndigheten.se>, 5.1.2e @folkhalsomyndigheten.se'
 < 5.1.2e @folkhalsomyndigheten.se>, 5.1.2e @folkhalsomyndigheten.se'
 < 5.1.2e @folkhalsomyndigheten.se>, 5.1.2e | 5.1.2e < 5.1.2e @ecdc.europa.eu>, 5.1.2e 5.1.2e
 < 5.1.2e @ecdc.europa.eu>, 5.1.2e | 5.1.2e < 5.1.2e @ecdc.europa.eu>, 5.1.2e 5.1.2e
 < 5.1.2e @ecdc.europa.eu>, 5.1.2e | 5.1.2e < 5.1.2e @ecdc.europa.eu>, PHF Support
 < 5.1.2e @ecdc.europa.eu>, Typing < 5.1.2e @ecdc.europa.eu>

Onderwerp: Placeholder - Extraordinary NFP for Microbiology meeting, 11 March at 15:00

To: ECDC NFP for Microbiology (members)
 cc: ECDC NFP for Microbiology (alternates), National Coordinators (members and alternates)

Dear National Microbiology Focal points,

I hope that this letter finds you well in these hectic times of Covid-19 pandemic.

This is a placeholder for an extraordinary NMFP meeting to discuss capacity building for whole genome sequencing in the EU/EEA countries. Rapidly detecting and quantifying the circulation of variants of concern (VOC) has emerged as an essential component in the response to the pandemic. At this point in time, it would play a significant role in rapidly controlling or delaying the spread of VOCs, thus allowing for a higher proportion of the population to be vaccinated in the meantime. In the longer term, ongoing monitoring of VOC would be essential for informing vaccination strategies and vaccine development.

Following the European Commission recommendations that Member States should mobilise resources to ensure a sequencing capacity of 5-10% of positive SARS-CoV-2 test results, we would like to collect the specific infrastructure and training needs for your country. Therefore the purpose for this meeting is to identify together the main priorities in terms of infrastructural developments in your countries in order to facilitate a more informed and effective allocation of European resources. We should aim for reaching in the shortest time possible a sustainable development of Member States capacities for sequencing SARS-CoV-2 isolates, while at the same time ensuring that such developments contribute to the overall strengthening of public health microbiology capacity beyond the ongoing pandemic.

The meeting will be followed by individual country interviews where you will be asked to provide the specific needs of your country. A final agenda and background material will be sent to you shortly.

Draft agenda:



Kind regards

5.1.2e | 5.1.2e
5.1.2e
Surveillance section, Public Health Functions (PHF) Unit



European Centre for Disease Prevention and Control (ECDC)
Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 [redacted] 5.1.2e / Fax +46 [redacted] 5.1.2e
www.ecdc.europa.eu

Follow ECDC on: [f](#) [t](#) [in](#) [yt](#)

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.